A Note on Sample Size Determination for Bioequivalence Studies with Higher-Order Crossover Designs

By Chen Keh-Wei   Chow Shein-Chung   Li Gang  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 25, Iss. 6, 1997-12 ,pp. : 753-765

Springer Publishing Company

Access to resources Recommend Favorite

Ambroxol Lozenge Bioavailability: An Open-Label, Two-Way Crossover Study of the Comparative Bioavailability of Ambroxol Lozenges and Commercial Tablets in Healthy Thai Volunteers

By Rojpibulstit M.   Kasiwong S.   Juthong S.   Phadoongsombat N.   Faroongsarng D.  

Clinical Drug Investigation, Vol. 23, Iss. 4, 2003-01 ,pp. : 273-280

Adis International

Access to resources Recommend Favorite

Crossover Versus Parallel Designs: Dose-Escalation Design Comparisons for First-In-Human Studies

By Yan Zhiwu   Hosmane Balakrishna   Locke Charles  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 4, 2013-07 ,pp. : 804-817

Taylor & Francis Ltd

Access to resources Recommend Favorite

Comparative Bioavailability of Lornoxicam as Single Doses of Quick-Release Tablet, Standard Tablet and Intramuscular Injection: A Randomized, Open-Label, Crossover Phase I Study in Healthy Volunteers

By Radhofer-Welte Susanna  

Clinical Drug Investigation, Vol. 28, Iss. 6, 2008-01 ,pp. : 345-351

Adis International

Access to resources Recommend Favorite

Optimal Designs in Stability Studies

By Hedayat A. S.  

Journal of Biopharmaceutical Statistics, Vol. 16, Iss. 1, 2006-01 ,pp. : 35-59

Taylor & Francis Ltd

Access to resources Recommend Favorite